Disease · MONDO_0010604
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Factor On-demand vs Fitusiran 80 mg Prophylaxis: deaths from any cause | 0 of 40 | 0 of 79 | 119 | NCT03417245 | Trial comparisons |
| Factor On-demand vs Fitusiran 80 mg Prophylaxis: serious adverse events | 5 of 40 | 5 of 79 | 119 | NCT03417245 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: deaths from any cause | 1 of 34 | 1 of 51 | 85 | NCT02141074 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: serious adverse events | 9 of 34 | 19 of 51 | 85 | NCT02141074 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: Number of Participants With Incidence of Inhibitory Antibodies Against FIX (At End of Trial) | 2 of 20 | 2 of 51 | 71 | NCT02141074 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: Number of Participants With Incidence of Inhibitory Antibodies Against FIX (100 ED) | 2 of 19 | 2 of 47 | 66 | NCT02141074 | Trial comparisons |
| Pre-prophylaxis vs Prophylaxis: Number of Participants With Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) (50 Exposure Days) | 2 of 34 | 0 of 28 | 62 | NCT02141074 | Trial comparisons |
| Bypassing Agents (BPA) On-demand vs Fitusiran 80 mg Prophylaxis: deaths from any cause | 0 of 19 | 0 of 41 | 60 | NCT03417102 | Trial comparisons |
| Bypassing Agents (BPA) On-demand vs Fitusiran 80 mg Prophylaxis: serious adverse events | 5 of 19 | 7 of 41 | 60 | NCT03417102 | Trial comparisons |
| Original Dose Regimen (SAS 1) vs AT-Based Dose Regimen (SAS 2): Number of Participants With Potentially Clinically Significant Abnormality: Physical Examination | 17 of 34 | 2 of 18 | 52 | NCT02554773 | Trial comparisons |
| Original Dose Regimen (SAS 1) vs AT-Based Dose Regimen (SAS 2): deaths from any cause | 1 of 34 | 0 of 18 | 52 | NCT02554773 | Trial comparisons |
| Original Dose Regimen (SAS 1) vs AT-Based Dose Regimen (SAS 2): Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis | 0 of 34 | 0 of 18 | 52 | NCT02554773 | Trial comparisons |
| Original Dose Regimen (SAS 1) vs AT-Based Dose Regimen (SAS 2): serious adverse events | 13 of 34 | 1 of 18 | 52 | NCT02554773 | Trial comparisons |
| Arm 1: up to 3 x 90 Micrograms/kg rFVIIa BI vs Arm 2: 1 x 270 Micrograms/kg rFVIIa BI: serious adverse events | 2 of 18 | 2 of 20 | 38 | NCT01757405 | Trial comparisons |
| Participants < 6 Years Old vs Participants 6 to < 12 Years Old: serious adverse events | 3 of 15 | 1 of 15 | 30 | NCT01440946 | Trial comparisons |
| Younger Children (0-6 Years) vs Older Children (7-12 Years): Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU) | 0 of 12 | 0 of 13 | 25 | NCT01467427 | Trial comparisons |
| Younger Children (0-6 Years) vs Older Children (7-12 Years): Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU) | 0 of 12 | 0 of 13 | 25 | NCT01467427 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010604/comparisons